The Investment Column: Chiroscience still seeking a partner
Thursday 02 October 1997
With the drug largely through critical final-stage trials and demonstrably safer than alternatives, it will be filed for approval in Europe by the year-end and in the US next April. So where is the high profile tie-up? Though Dr John Padfield, Chiroscience's chief executive, says he is talking to a variety of potential partners, he hinted yesterday that the final deal might be lower key than people expect.
Rather than a marketing alliance, Chiroscience is considering developing levobupivacaine jointly with a pain management specialist who would also be responsible for marketing. Though a deal with a major drug group would give Chiroscience a useful royalty stream, it might in the end extract less value. With cures for cancer and HIV the holy grails of research, pain control is low priority for many drug majors. Levobupivacaine, with estimated peak sales of pounds 200m, might be too small for them to bother with.
Meanwhile, Chiroscience needs to think about its funding needs. With cash burn running at some pounds 2m a month, the group's cash pile won't last long. Though its attractive drug pipeline could attract more alliances, the fastest way to boost cash reserves would be demerging or selling its profitable ChiroTech business, which solves chemical problems for the fragrances and flavourings industry. The shares, down 4p to 273.5p are fair value.
- 1 Hair loss explained: How and why men go bald
- 2 Game of Thrones season 6: Jon Snow theorists believe Ned Stark's son may have a twin sister
- 3 Artist takes LSD, draws herself over different stages of the 9-hour trip to show its effects
- 4 iPhone 6s camera: features to include 4K video camera and flash for selfies
- 5 A pint of water every day is the key to losing weight, scientists say
Most expensive city to live in for expatriates: Luanda, Angola takes number one spot with Hong Kong and Zurich in top three
Video of Irish 'professional boxer' fighting Istanbul neighbourhood goes viral in Turkey
If Surrey were Syria: Social experiment shows what it's like to live under siege
Irish tourist filmed fighting with shopkeepers in Turkey says they 'messed with the wrong man'
House of Lords: Outcry as donors, fixers and MPs caught up in expenses scandal get peerages
Dresden riots: Protesters in Germany attack refugee buses shouting 'foreigners out'
France train shooting: US soldiers speak of the moment they stopped gunman and 'beat him until he was unconscious'
Labour leadership: Jeremy Corbyn accused of 'deluding' young supporters with 'claptrap'
'Women only' train carriages: Jeremy Corbyn unveils radical move to tackle public harassment
Black holes are a passage to another universe, says Stephen Hawking
Iain Duncan Smith 'should resign over disability benefit death figures', says Jeremy Corbyn
iJobs Money & Business
£25000 - £30000 per annum: Recruitment Genius: From modest beginnings the comp...
£35000 - £40000 per annum: Recruitment Genius: From modest beginnings the comp...
£15000 - £65000 per annum: Recruitment Genius: This is an exciting opportunity...
£18000 - £20000 per annum: Recruitment Genius: This is a fantastic opportunity...